Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Cazzola

Showing results (581-590 of 645) with videos related to

Pageof 65
Sort By:
Blood|January 13, 2011
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutationsFrancesco Passamonti, Chiara Elena, Susanne Schnittger, et al.
Leukemia|December 22, 2020
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2<sup>P95</sup>-mutated neoplasmsGabriele Todisco, Maria Creignou, Anna Gallì, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2017
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary MyelofibrosisPaola Guglielmelli, Terra L Lasho, Giada Rotunno, et al.
American Journal of Hematology|April 3, 2016
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM groupGiada Rotunno, Annalisa Pacilli, Valentina Artusi, et al.
Blood|May 10, 2015
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblastsLuca Malcovati, Mohsen Karimi, Elli Papaemmanuil, et al.
American Journal of Hematology|April 23, 2013
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromeEmilio Paolo Alessandrino, Matteo G Della Porta, Luca Malcovati, et al.
Blood|February 22, 2014
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-RMatteo G Della Porta, Emilio Paolo Alessandrino, Andrea Bacigalupo, et al.
Blood|July 3, 2014
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisElisa Rumi, Daniela Pietra, Cristiana Pascutto, et al.
Blood|July 8, 2016
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemiaChiara Elena, Anna Gallì, Esperanza Such, et al.
Blood|May 9, 2019
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasmsFiorella Schischlik, Roland Jäger, Felix Rosebrock, et al.
Pageof 65

Showing results (581-590 of 645) with videos related to

Sort By:
Pageof 65
Blood|January 13, 2011
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutationsFrancesco Passamonti, Chiara Elena, Susanne Schnittger, et al.
Leukemia|December 22, 2020
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2<sup>P95</sup>-mutated neoplasmsGabriele Todisco, Maria Creignou, Anna Gallì, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2017
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary MyelofibrosisPaola Guglielmelli, Terra L Lasho, Giada Rotunno, et al.
American Journal of Hematology|April 3, 2016
Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM groupGiada Rotunno, Annalisa Pacilli, Valentina Artusi, et al.
Blood|May 10, 2015
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblastsLuca Malcovati, Mohsen Karimi, Elli Papaemmanuil, et al.
American Journal of Hematology|April 23, 2013
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromeEmilio Paolo Alessandrino, Matteo G Della Porta, Luca Malcovati, et al.
Blood|February 22, 2014
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-RMatteo G Della Porta, Emilio Paolo Alessandrino, Andrea Bacigalupo, et al.
Blood|July 3, 2014
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisElisa Rumi, Daniela Pietra, Cristiana Pascutto, et al.
Blood|July 8, 2016
Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemiaChiara Elena, Anna Gallì, Esperanza Such, et al.
Blood|May 9, 2019
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasmsFiorella Schischlik, Roland Jäger, Felix Rosebrock, et al.
Pageof 65